Form 4: Provectus Biopharmaceuticals Director Acquires Convertible Preferred Stock

Director Webster Bailey reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Summary

• On September 30, 2024, Webster Bailey, a director of Provectus Biopharmaceuticals, acquired Series D-1 Convertible Preferred Stock.
• Bailey now beneficially owns 158,618 shares of common stock directly.
• The transaction involved the acquisition of 117,295 shares of Series D-1 Convertible Preferred Stock, each convertible into 10 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a director's acquisition of convertible preferred stock. The sentiment is neutral as it simply reports a transaction.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of convertible preferred stock by a director could be viewed positively by shareholders, signaling confidence in the company's future performance.
• The conversion of preferred stock into common stock in the future will dilute existing shareholders.

Key Dates